Volume 9 Issue 4
Jul.  2018
Turn off MathJax
Article Contents
Hu Linkun, Chen Cheng, Wang Weizhen, et al. Study on the relationship between anti-inflammatory cytokine IL-35 and delayed renal graft function[J]. ORGAN TRANSPLANTATION, 2018, 9(4): 272-277. doi: 10.3969/j.issn.1674-7445.2018.04.006
Citation: Hu Linkun, Chen Cheng, Wang Weizhen, et al. Study on the relationship between anti-inflammatory cytokine IL-35 and delayed renal graft function[J]. ORGAN TRANSPLANTATION, 2018, 9(4): 272-277. doi: 10.3969/j.issn.1674-7445.2018.04.006

Study on the relationship between anti-inflammatory cytokine IL-35 and delayed renal graft function

doi: 10.3969/j.issn.1674-7445.2018.04.006
More Information
  • Corresponding author: Hou Jianquan,Email:xf192@163.com
  • Received Date: 2018-03-23
    Available Online: 2021-01-19
  • Publish Date: 2018-07-15
  •   Objective  To investigate the relationship between the interleukin (IL)-35 and the recovery of renal graft function.  Methods  Clinical data of 45 recipients receiving renal transplantation from donation after cardiac death (DCD) were retrospectively analyzed. According to the presence of delayed graft function (DGF) after renal transplantation, all recipients were divided into the immediate graft function (IGF) group (n=32) and DGF group (n=13). The serum creatinine (Scr) level and estimated glomerular filtration rate (eGFR) in the recipients were statistically compared between two groups at 1, 2, 3, 7, 14, 28 d and 3, 6 and 12 months after renal transplantation. The IL-35 levels in the serum and urine samples of the recipients were statistically compared between two groups at 1, 2, 3, 7, 14, 28 d following renal transplantation.  Results  In the DGF group, the renal function was restored slowly. Compared with the IGF group, the Scr level was significantly higher, whereas the eGFR was considerably lower in the DGF group at postoperative 7 d (both P < 0.05). At 1 year after surgery, there was no significant difference in the Scr level between two groups. Compared with the IGF group, the eGFR in the DGF group was significantly lower at postoperative 1 year (P < 0.05). At 1, 2, 3, 7, 14 d after operation, the serum levels of IL-35 in the DGF group were evidently lower than those in the IGF group (all P < 0.05). Compared with the IGF group, the serum level of IL-35 in the DGF group was significantly increased at postoperative 28 d (P < 0.05). At postoperative 1, 2, 3, 7 d, the IL-35 levels in the urine samples in the DGF group were significantly lower than those in the IGF group (all P < 0.05). At postoperative 14 and 28 d, the IL-35 levels in the urine samples did not significantly differ between two groups (both P > 0.05).  Conclusions  The low levels of IL-35 in the serum and urine of recipients after renal transplantation are associated with the incidence of DGF to certain extent, prompting that excessively weak systemic and local anti-inflammatory responses early after renal transplantation and uncontrolled excessive inflammatory response are probably the pivotal causes of DGF.

     

  • loading
  • [1]
    YARLAGADDA SG, COCA SG, FORMICA RN JR, et al. Association between delayed graft function and allograft and patient survival: a systematic review and Meta-analysis[J]. Nephrol Dial Transplant, 2009, 24(3): 1039-1047. DOI: 10.1093/ndt/gfn667.
    [2]
    COLLINS AJ, FOLEY RN, HERZOG C, et al. US Renal Data System 2010 Annual Data Report[J]. Am J Kidney Dis, 2011, 57(1 Suppl 1): A8, e1-e526. DOI: 10.1053/j.ajkd.2010.10.007.
    [3]
    SIEDLECKI A, IRISH W, BRENNAN DC. Delayed graft function in the kidney transplant[J]. Am J Transplant, 2011, 11(11): 2279-2296. DOI: 10.1111/j.1600-6143.2011.03754.x.
    [4]
    LINFERT D, CHOWDHRY T, RABB H. Lymphocytes and ischemia-reperfusion injury[J]. Transplant Rev (Orlando), 2009, 23(1): 1-10. DOI: 10.1016/j.trre.2008.08.003.
    [5]
    KINSEY GR, SHARMA R, HUANG L, et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury[J]. J Am Soc Nephrol, 2009, 20(8): 1744-1753. DOI: 10.1681/ASN.2008111160.
    [6]
    COLLISON LW, WORKMAN CJ, KUO TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169): 566-569. doi: 10.1038/nature06306
    [7]
    WU S, LI Y, LI Y, et al. Interleukin-35 attenuates collagen-induced arthritis through suppression of vascular endothelial growth factor and its receptors[J]. Int Immunopharmacol, 2016, 34:71-77. DOI: 10.1016/j.intimp.2016.02.018.
    [8]
    MA YC, ZUO L, CHEN JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006, 17(10): 2937-2944. doi: 10.1681/ASN.2006040368
    [9]
    GROSSO G, CORONA D, MISTRETTA A, et al. Delayed graft function and long-term outcome in kidney transplantation[J]. Transplant Proc, 2012, 44(7): 1879-1883. DOI: 10.1016/j.transproceed.2012.06.044.
    [10]
    陈国栋, 袁小鹏, 李军, 等.心脏死亡器官捐献供肾与传统尸体供肾肾移植的疗效比较[J].中华器官移植杂志, 2013, 34(7): 392-395. DOI: 10.3760/cma.j.issn.0254-1785.2013.07.003.CHEN

    CHEN GD, YUAN XP, LI J, et al. Comparison of long-term efficacy and complications after kidney transplantation between donors after cardiac death and traditional deceased donors[J]. Chin J Organ Transplant, 2013, 34(7): 392-395. DOI: 10.3760/cma.j.issn.0254-1785.2013.07.003.
    [11]
    GUERRIERI D, RE L, PETRONI J, et al. Gene expression profile in delay graft function: inflammatory markers are associated with recipient and donor risk factors[J]. Mediators Inflamm, 2014: 167361. DOI: 10.1155/2014/167361.
    [12]
    PATSCHAN D, PATSCHAN S, MÜLLER GA. Inflammation and microvasculopathy in renal ischemia reperfusion injury[J]. J Transplant, 2012: 764154. DOI: 10.1155/2012/764154.
    [13]
    KIELAR ML, JOHN R, BENNETT M, et al. Maladaptive role of IL-6 in ischemic acute renal failure[J]. J Am Soc Nephrol, 2005, 16(11): 3315-3325. doi: 10.1681/ASN.2003090757
    [14]
    ASCON M, ASCON DB, LIU M, et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes[J]. Kidney Int, 2009, 75(5): 526-535. DOI: 10.1038/ki.2008.602.
    [15]
    RABB H, GRIFFIN MD, MCKAY DB, et al. Inflammation in AKI: current understanding, key questions, and knowledge gaps[J]. J Am Soc Nephrol, 2016, 27(2): 371-379. DOI: 10.1681/ASN.2015030261.
    [16]
    NIEDBALA W, WEI XQ, CAI B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[J]. Eur J Immunol, 2007, 37(11): 3021-3029. doi: 10.1002/(ISSN)1521-4141
    [17]
    THIOLAT A, DENYS A, PETIT M, et al. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice[J]. Cytokine, 2014, 69(1): 87-93. DOI: 10.1016/j.cyto.2014.05.015.
    [18]
    JAFARZADEH A, JAMALI M, MAHDAVI R, et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program[J]. J Mol Neurosci, 2015, 55(4): 891-897. DOI: 10.1007/s12031-014-0443-z.
    [19]
    HU Y, DONG C, YUE Y, et al. In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells[J]. Arch Virol, 2014, 159(9): 2411-2419. DOI: 10.1007/s00705-014-2098-z.
    [20]
    LIU Y, WU Y, WANG Y, et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects[J]. Leukemia, 2015, 29(4): 939-946. DOI: 10.1038/leu.2014.310.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Article Metrics

    Article views (114) PDF downloads(10) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return